Markus Ruehle

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Sundar Jagannath, Leonard T. Heffner, Sikander Ailawadhi et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 83 citations

Medicine, Oncology, Pharmacotherapy +9

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Leonard T. Heffner, Sundar Jagannath, Todd M. Zimmerman et al. · Blood · 2012 · 60 citations

Pharmacy, Oncology, Pharmacology +12

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Kevin R. Kelly, Sikander Ailawadhi, David S. Siegel et al. · The Lancet Haematology · 2021 · 46 citations

Medicine, Oncology, Pharmacotherapy +15

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, Asher Chanan‐Khan, Leonard T. Heffner et al. · Blood · 2011 · 44 citations

Medicine, Hematology, Oncology +14

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

Kevin R. Kelly, Asher Chanan‐Khan, George Somlo et al. · Blood · 2013 · 30 citations

Medicine, Oncology, Pharmacotherapy +14